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Two of the clinical sessions focused on endocrine therapy of
breast cancer. It is clear that whereas endocrine therapy
represents a crucial modality in breast cancer management,
with substantial success to date, there is still much to be
learned and great potential for increasing its value to patients.
This therapeutic gain will probably come from a better under-
standing of resistance to endocrine therapy, both de novo
and acquired; better selection of the right endocrine agent for
the right patient; and better management of adverse events
and noncompliance. Importantly, endocrine therapy is an
important backbone upon which targeted therapy combina-
tions will be built. These sessions addressed many of these
important issues.
Professor Craig Jordan [1] considered the most important
lessons learned from studying the action of oestrogen on
breast cancer cells as a basis for future research. He reviewed
the mechanisms of action of oestrogen through the oestrogen
receptor (ER) and the complexity of these interactions. A new
concept of evolution of resistance to selective ER modulators
was considered, and it was noted that oestradiol can kill both
selective ER modulator stimulated and aromatase inhibitor (AI)
resistant cells. The current status of endocrine therapy in the
adjuvant and prevention settings was reviewed, and
angiogenesis inhibition and apoptosis induction were
considered as future promising areas of research.
Professor James Ingle [2] emphasized the fact that variability
exists in how patients respond to endocrine therapy, and that
there is variability in terms of the effects of endocrine agents
on end organs and adverse events. He reviewed the
concepts of pharmacogenetics, pharmacogenomics, pharma-
codynamics and pharmacokinetics. The field of pharmaco-
genetics/genomics addresses the genetic factors of the host
and has the goal of identifying the right drug at the right dose
for the right patient. It is clear that the field is at an early stage
for endocrine therapy of breast cancer, but there is emerging
evidence that cytochrome P450-2D6 metabolizer status is of
predictive value in patients considering tamoxifen therapy.
Further validation of these findings is needed before there
can be widespread acceptance. The field is at an earlier
stage of development for the AIs but research is ongoing.
Professor Daniel Hayes [3] addressed the issue of markers of
endocrine sensitivity. He considered the topics of endocrine
resistance and definitions of tumour markers, including levels
of evidence and the importance of determining whether a
marker is prognostic or predictive. The ER was considered to
be the most important predictive factor for endocrine therapy,
and he reviewed the weaknesses that exist with this marker.
Candidate markers most likely to complement the ER were
considered.
Professor William Miller [4] addressed the identification and
mechanisms of endocrine resistance that are central to
advancing the efficacy of endocrine therapy in breast cancer.
He considered endocrine resistance from the standpoints of
primary and acquired resistance, and categories of clinical,
proliferative and molecular resistance. The mechanisms of
resistance were considered in terms of inherent hormone
insensitivity, nonendocrine growth signalling, ER activation/
hypersensitivity and inefficient/compromised therapy. Impor-
tantly, he reviewed our current understanding of means to
identify these different categories of resistance.
Professor Stephen Johnston [5] addressed the status of
research into targeting the ER and signalling pathways simul-
taneously. The clinical progress to date was summarized,
considering both studies that revealed negative results as
well as those that revealed positive results. In particular, trials
with AIs and epidermal growth factor receptor/HER-2 (human
epidermal growth factor-2) targeted therapy appear to offer
substantial potential for progress. He presented the concepts
of ‘vertical growth factor pathway blockade’ and ‘horizontal
pathway blockade’ as being important approaches to
targeting multiple signalling pathways.
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